Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.
Press releases published on May 27, 2025
Strongline returns to market, signs deal with QLog to ensure leading staff duress offering is available to health systems around the country
GlobeNewswire
·
May 27, 2025
SAN FRANCISCO, May 27, 2025 (GLOBE NEWSWIRE) -- Commure announced today a strategic partnership and licensing agreement with QLog, a leading Israeli innovator in real-time location systems (RTLS) and Bluetooth Low Energy (BLE) technologies for healthcare. …
BioNTech präsentiert auf der ASCO-Jahrestagung 2025 Fortschritte aus der diversifizierten Onkologie-Pipeline
GlobeNewswire
·
May 27, 2025
MAINZ, Deutschland, 27. Mai 2025 -- BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird auf der Jahrestagung der American Society of Clinical Oncology („ASCO“), die vom 30. Mai bis 3. Juni 2025 in Chicago, Illinois, stattfindet, klinische …
BioNTech to Present Progress Across Diversified Oncology Pipeline at the 2025 ASCO Annual Meeting
GlobeNewswire
·
May 27, 2025
MAINZ, Germany, May 27, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data from select pipeline candidates across the Company’s diversified oncology portfolio at the American Society of Clinical Oncology (“ASCO …
Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation
GlobeNewswire
·
May 27, 2025
NEEDHAM, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today …
IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025
GlobeNewswire
·
May 27, 2025
Presentation at ESMO will follow oral 2025 ASCO Annual Meeting presentation highlighting unprecedented survival data from Phase 2 OVATION 2 Study of IMNN-001 Simultaneously publication in leading peer-reviewed journal Gynecologic Oncology details IMNN-001’ …
BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
GlobeNewswire
·
May 27, 2025
DSMB recommended the continuation of trial as planned Topline data expected in Q3 2025 NEW HAVEN, Conn., May 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop …
XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million
GlobeNewswire
·
May 27, 2025
EMERYVILLE, Calif. and LUND, Sweden, May 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery …
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
GlobeNewswire
·
May 27, 2025
SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to …
Nautilus Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewswire
·
May 27, 2025
SEATTLE, May 27, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating in the …
NeurAxis to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025
GlobeNewswire
·
May 27, 2025
CARMEL, Ind., May 27, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults …
Merus to Present at Upcoming Investor Conferences
GlobeNewswire
·
May 27, 2025
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics …
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
GlobeNewswire
·
May 27, 2025
NAARDEN, the Netherlands and MIAMI, May 27, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at …
Emory Healthcare Researchers Use Dynamic Digital Radiography to Compare Shoulder Improvement of Two Surgical Interventions for Massive Irreparable Rotator Cuff Tears
GlobeNewswire
·
May 27, 2025
WAYNE, N.J., May 27, 2025 (GLOBE NEWSWIRE) -- Konica Minolta Healthcare Americas, Inc., congratulates Emory Healthcare researchers on the publication of a new study using Dynamic Digital Radiography (DDR) to compare shoulder biomechanics in patients after …
Merus hält Vorträge auf bevorstehenden Investorenkonferenzen
GlobeNewswire
·
May 27, 2025
UTRECHT, Niederlande und CAMBRIDGE, Massachusetts, May 27, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), ein Unternehmen für klinische Onkologie, das innovative, multispezifische Antikörper in voller Länge sowie Antikörper-Wirkstoff-Konjugate ( …
Theriva™ Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review Topline Data from the VIRAGE Phase 2b Trial of VCN-01 in Metastatic Pancreatic Cancer
GlobeNewswire
·
May 27, 2025
- Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in a poster session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on Saturday, May …
Theriva™ Biologics anuncia la presentación de los datos del ensayo clínico de Fase 1 del VCN-01 para el retinoblastoma en ASCO 2025 y la reunión de investigadores para revisar los datos preliminares del ensayo VIRAGE de Fase 2b del VCN-01 para el…
GlobeNewswire
·
May 27, 2025
- Los resultados clínicos y de seguridad del estudio de Fase 1 del VCN-01 (zabilugene almadenorepvec) en pacientes con retinoblastoma refractario se presentarán en una sesión de pósteres en la reunión anual de la Sociedad Americana de Oncología Clínica ( …
Immutep’s Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma
GlobeNewswire
·
May 27, 2025
Novel combination with efti has met the trial’s primary endpoint of tumour hyalinization/fibrosis in the neoadjuvant setting for patients with resectable soft tissue sarcoma Detailed results are planned for presentation at a future medical meeting SYDNEY, …
ORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC
GlobeNewswire
·
May 27, 2025
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced …
LENZ Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire
·
May 27, 2025
SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop …
Junshi Biosciences Announces Ongericimab’s sNDA Approval in China
GlobeNewswire
·
May 27, 2025
SHANGHAI, May 27, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel …